Developer docs
API playgroundTry for free, no card

Search company profiles

iQure Pharma

Full company profile

uuid0000sbt

Namestring
iQure Pharma
Legal namestring
iQure Pharma Inc.
Websiteurl
iqurepharma.com
Company typeenum
Private
Founded yearint
2019
Descriptiontext

iQure Pharma is a clinical-stage biotech company developing first-in-class astrocyte-targeted therapeutics designed to restore glutamate balance in central nervous system (CNS) disorders. The company's science is centered on EAAT2 (excitatory amino acid transporter 2), the main astrocytic transporter responsible for clearing excess synaptic glutamate, with the goal of breaking the excitotoxicity feedback loop that drives neuronal dysfunction across epilepsy, Parkinson's disease, migraine, and ALS. Its lead asset, iQ-007, is a first-in-class, orally available EAAT2 positive allosteric modulator currently in early clinical development (Phase 1 in treatment-resistant epilepsy, with Phase 2 proof-of-concept preparation underway); a second preclinical program, iQ-008, targets neuropathic pain and neurodegenerative disease.

The company was founded in 2019 and is headquartered in Princeton, New Jersey (incorporated in Delaware), operating with a small team of 1-10 employees. Its platform is grounded in peer-reviewed research published in Annals of Neurology in collaboration with Harvard Medical School, NIH, Boston Children's Hospital, and Jagiellonian University, where Prof. Krzysztof Kaminski — the inventor of iQ-007 — is based. iQure has secured composition-of-matter patent protection for iQ-007 in the United States (granted 2025) and has been awarded a research grant from The Michael J. Fox Foundation for Parkinson's Research (announced June 2026), with Atuka Inc. as a preclinical collaboration partner. Additional academic partnerships include the University of Padova (Dr. Laura Civiero) for mechanistic and patient-stratification work.

iQure is pre-revenue and follows a licensing/royalty-oriented business model typical of clinical-stage biotechs: it has no commercial products, no disclosed pricing, and expects eventual monetization through partnership deals or product commercialization. To date the company has raised approximately $5 million-plus across multiple funding rounds from 2020 through 2026, including a Series A early closing led by Keiretsu Mid-Atlantic (over $600K in 2022), $1.2 million from Ventura BioMed Investors and OKG Capital (2023), and several SEC-registered exempt securities offerings combining debt and equity. Non-dilutive funding has come from NIH programs and The Michael J. Fox Foundation. Its go-to-market motion is centered on scientific publication, conference partnering (BIO International, JPM Week, Biotech Showcase), and direct engagement with pharmaceutical partners and investors.

Short descriptiontext

iQure Pharma is a clinical-stage biotech developing first-in-class astrocyte-targeted EAAT2 modulators to treat CNS disorders, with lead asset iQ-007 in Phase 1 for treatment-resistant epilepsy and expansion plans for Parkinson's disease, migraine, and ALS.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
1–10
akta.pro rankint
HeadquartersPrinceton, United States
HQ citystring
Princeton
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Offices1 record

Each record includes

City, Country, Type, Description, Source

Keyword5 values
CNS therapeutics development, EAAT2 modulator platform, epilepsy clinical trials, astrocyte targeted therapy, neurodegenerative disease drug
Industry2 codes
PRIMARYHLAAACAH
Neurology/CNS Gene Therapies
Healthcare & Life Sciences/Biotechnology & Biologics/Gene Therapy (AAV/lentiviral/other vectors)
SECONDARYHLACAFAL
Connected Therapeutics & Smart Drug Delivery Monitoring
Healthcare & Life Sciences/Digital Health & Health IT/Remote Patient Monitoring (RPM) & Connected Care Platforms
NAICS code2 codes
  • Navigational, Measuring, Electromedical, and Control Instruments Manufacturing33451
  • Electromedical and Electrotherapeutic Apparatus Manufacturing334510
SIC code1 code
  • Pharmaceutical Preparations2834
Product category
CNS Therapeutics
Social media profiles1 record
GTM motion1 record

Each record includes

Type, Description, Source

Revenue model1 record
1Drug Development and Licensing
TypeLicensing Royalties
Description

Pre-revenue clinical-stage biotech company developing CNS therapeutics. Revenue expected from licensing deals, partnerships, or eventual product commercialization.

iqurepharma.com
Marketing channels4 records

Each record includes

Title, Type, Stage, Description, Source

Cost components4 values
Technology or R&D, Personnel, Operations, Marketing or Sales
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Core offering1 text field

iQure Pharma is a clinical-stage biotech company developing first-in-class, orally available small-molecule EAAT2 positive allosteric modulators designed to restore astrocytic glutamate uptake and break the cycle of excitotoxicity in central nervous system disorders. Its lead asset iQ-007 is in Phase 1 clinical development for treatment-resistant epilepsy, with mechanism-driven pipeline expansion into Parkinson's disease, migraine, and ALS, and a second preclinical asset iQ-008 targeting neuropathic pain and neurodegenerative diseases.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 2 values shown
  • Strong preclinical efficacy demonstrated across Parkinson's disease, epilepsy, and migraine models
+1 more record
Product overview1 text field

iQure Pharma is a clinical-stage biotech company developing first-in-class astrocyte-targeted therapeutics designed to restore glutamate balance in CNS disorders. The company's science targets EAAT2, the main astrocytic glutamate transporter, to break the cycle of excitotoxicity. The core product is iQ-007, an orally available EAAT2 positive allosteric modulator currently in early clinical development for epilepsy, with expansion strategies for Parkinson's disease, migraine, and ALS. The pipeline includes iQ-007 as the lead asset in clinical development and iQ-008 in preclinical development for neuropathic pain and neurodegenerative diseases.

Product and service2 records
1iQ-007
CategoryCore product (CNS small molecule therapeutic)
Description

First-in-class, orally available EAAT2 positive allosteric modulator designed to restore astrocytic glutamate uptake and break the excitotoxicity cycle. Currently in Phase 1 clinical development for treatment-resistant epilepsy, with mechanism-driven expansion strategies into Parkinson's disease, migraine, and ALS.

2iQ-008
CategoryPipeline product (CNS small molecule therapeutic)
Description

Preclinical-stage therapeutic program targeting neuropathic pain, epilepsy, and neurodegenerative diseases through EAAT2 modulation.

Scale indicator6 records

Each record includes

Type, Value, Description, Source

Partnership5 partners
Strategic tierSupportingTypeStrategic or Co-development PartnerAnnounced on2026-06-18
Description

Collaboration partner with iQure Pharma on the EAAT2 modulator program for Parkinson's disease, working on preclinical studies across multiple disease-relevant models.

Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2025-10-14
Description

Research collaboration with Associate Professor Laura Civiero from the University of Padova focusing on iQ-007 targeting EAAT2 to further elucidate its underlying mechanism of action. The collaboration aims to better identify and stratify patients who could benefit from this novel astrocyte-targeted therapy while providing deeper insight into molecular pathways governing glutamate uptake.

3Harvard Medical School
Strategic tierCoreTypeStrategic or Co-development Partner
Description

Research collaboration supporting peer-reviewed research validating EAAT2 mechanism as a novel antiseizure strategy. Published in Annals of Neurology.

iqurepharma.com
Strategic tierSupportingTypeStrategic or Co-development Partner
Description

Research collaboration supporting peer-reviewed research validating EAAT2 mechanism as a novel antiseizure strategy. Published in Annals of Neurology.

Strategic tierCoreTypeStrategic or Co-development Partner
Description

Co-author of peer-reviewed research published in Annals of Neurology validating EAAT2 mechanism as novel antiseizure strategy. Home of Prof. Krzysztof Kaminski, iQ-007 inventor.

Recent move6 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight6 records

Each record includes

Type, Description

Peers10 records
TypeDirect peer
Description

Clinical-stage biopharmaceutical company developing medicines for rare neurological and CNS disorders. Comparable as a small-cap CNS biotech pursuing novel mechanisms in neurology.

TypeDirect peer
Description

Clinical-stage CNS biotech developing therapies for epilepsy and other central nervous system disorders. Directly comparable as a similarly staged neurology-focused company pursuing novel CNS mechanisms with a small-cap, pipeline-driven profile.

TypeBroad incumbent
Description

Global biopharmaceutical company with a leading CNS/epilepsy franchise (Vimpat, Briviact, Fintepla). Major incumbent in the treatment-resistant epilepsy space iQure is pursuing.

TypeDirect peer
Description

Clinical-stage CNS company developing treatments for neurological conditions including epilepsy. Comparable as a focused CNS clinical-stage biotech with similar indication overlap and small-cap profile.

5SK Biopharmaceuticals
TypeBroad incumbent
Description

Global biopharmaceutical company focused on CNS therapies including the antiseizure medication Xcopri. Broader incumbent competing in the same epilepsy market iQ-007 is targeting.

TypeBroad incumbent
Description

Specialty pharmaceutical company with a significant CNS franchise including epilepsy products (e.g., Epidiolex). Larger incumbent operating across overlapping CNS indications with established commercialization channels.

TypeBroad incumbent
Description

CNS-focused biopharmaceutical company (now part of Biogen) with approved neurology assets. Broader incumbent operating in overlapping CNS space with much greater capital, scale, and commercialization infrastructure.

TypeDirect peer
Description

Clinical-stage CNS biopharmaceutical company with a focus on epilepsy and other neurological conditions. Directly comparable as a CNS-focused clinical biotech with active epilepsy pipeline assets.

TypeDirect peer
Description

Clinical-stage neuroscience company developing therapeutics for CNS disorders including epilepsy and neurodegenerative diseases. Comparable in stage, CNS focus, and small-team biotech execution model.

TypeDirect peer
Description

Clinical-stage biopharmaceutical company specializing in allosteric modulators for CNS disorders. Closely aligned with iQure's allosteric-modulator approach to CNS targets and similar small-cap development profile.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat3 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights6 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Segment1 record

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile3 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
No
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature3 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles3 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds10 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors8 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

iQure Pharma

CNS Therapeuticsiqurepharma.com

iQure Pharma is a clinical-stage biotech developing first-in-class astrocyte-targeted EAAT2 modulators to treat CNS disorders, with lead asset iQ-007 in Phase 1 for treatment-resistant epilepsy and expansion plans for Parkinson's disease, migraine, and ALS.

What iQure Pharma does

iQure Pharma is a clinical-stage biotech company developing first-in-class astrocyte-targeted therapeutics designed to restore glutamate balance in central nervous system (CNS) disorders. The company's science is centered on EAAT2 (excitatory amino acid transporter 2), the main astrocytic transporter responsible for clearing excess synaptic glutamate, with the goal of breaking the excitotoxicity feedback loop that drives neuronal dysfunction across epilepsy, Parkinson's disease, migraine, and ALS. Its lead asset, iQ-007, is a first-in-class, orally available EAAT2 positive allosteric modulator currently in early clinical development (Phase 1 in treatment-resistant epilepsy, with Phase 2 proof-of-concept preparation underway); a second preclinical program, iQ-008, targets neuropathic pain and neurodegenerative disease.

The company was founded in 2019 and is headquartered in Princeton, New Jersey (incorporated in Delaware), operating with a small team of 1-10 employees. Its platform is grounded in peer-reviewed research published in Annals of Neurology in collaboration with Harvard Medical School, NIH, Boston Children's Hospital, and Jagiellonian University, where Prof. Krzysztof Kaminski — the inventor of iQ-007 — is based. iQure has secured composition-of-matter patent protection for iQ-007 in the United States (granted 2025) and has been awarded a research grant from The Michael J. Fox Foundation for Parkinson's Research (announced June 2026), with Atuka Inc. as a preclinical collaboration partner. Additional academic partnerships include the University of Padova (Dr. Laura Civiero) for mechanistic and patient-stratification work.

iQure is pre-revenue and follows a licensing/royalty-oriented business model typical of clinical-stage biotechs: it has no commercial products, no disclosed pricing, and expects eventual monetization through partnership deals or product commercialization. To date the company has raised approximately $5 million-plus across multiple funding rounds from 2020 through 2026, including a Series A early closing led by Keiretsu Mid-Atlantic (over $600K in 2022), $1.2 million from Ventura BioMed Investors and OKG Capital (2023), and several SEC-registered exempt securities offerings combining debt and equity. Non-dilutive funding has come from NIH programs and The Michael J. Fox Foundation. Its go-to-market motion is centered on scientific publication, conference partnering (BIO International, JPM Week, Biotech Showcase), and direct engagement with pharmaceutical partners and investors.

iQure Pharma firmographics

Firmographics
Name
iQure Pharma
Legal name
iQure Pharma Inc.
Website
https://iqurepharma.com
Company type
Private
Founded year
2019
Operating status
Operating
Headcount range
1–10 employees
Short description
iQure Pharma is a clinical-stage biotech developing first-in-class astrocyte-targeted EAAT2 modulators to treat CNS disorders, with lead asset iQ-007 in Phase 1 for treatment-resistant epilepsy and expansion plans for Parkinson's disease, migraine, and ALS.
Ownership category
akta.pro rank

iQure Pharma industry classification

Industry
Product category
CNS Therapeutics
NAICS
Navigational, Measuring, Electromedical, and Control Instruments Manufacturing (33451), Electromedical and Electrotherapeutic Apparatus Manufacturing (334510)
SIC
Pharmaceutical Preparations (2834)
akta.pro industry
PRIMARYHLAAACAH
Neurology/CNS Gene Therapies
Healthcare & Life Sciences/Biotechnology & Biologics/Gene Therapy (AAV/lentiviral/other vectors)
SECONDARYHLACAFAL
Connected Therapeutics & Smart Drug Delivery Monitoring
Healthcare & Life Sciences/Digital Health & Health IT/Remote Patient Monitoring (RPM) & Connected Care Platforms

Keywords

  • CNS therapeutics development
  • EAAT2 modulator platform
  • Epilepsy clinical trials
  • Astrocyte targeted therapy
  • Neurodegenerative disease drug

Where iQure Pharma is headquartered

Location

Headquarters

HQ city
Princeton
HQ country
United States
HQ region
North America

Offices1 record

Markets served

iQure Pharma business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Technology or R&D, Personnel, Operations, Marketing or Sales

Revenue model

  1. Drug Development and Licensing: Pre-revenue clinical-stage biotech company developing CNS therapeutics. Revenue expected from licensing deals, partnerships, or eventual product commercialization.

Go-to-market motion1 record

Marketing channels4 records

iQure Pharma product offering

Product offering

Core offering

iQure Pharma is a clinical-stage biotech company developing first-in-class, orally available small-molecule EAAT2 positive allosteric modulators designed to restore astrocytic glutamate uptake and break the cycle of excitotoxicity in central nervous system disorders. Its lead asset iQ-007 is in Phase 1 clinical development for treatment-resistant epilepsy, with mechanism-driven pipeline expansion into Parkinson's disease, migraine, and ALS, and a second preclinical asset iQ-008 targeting neuropathic pain and neurodegenerative diseases.

Product overview

iQure Pharma is a clinical-stage biotech company developing first-in-class astrocyte-targeted therapeutics designed to restore glutamate balance in CNS disorders. The company's science targets EAAT2, the main astrocytic glutamate transporter, to break the cycle of excitotoxicity. The core product is iQ-007, an orally available EAAT2 positive allosteric modulator currently in early clinical development for epilepsy, with expansion strategies for Parkinson's disease, migraine, and ALS. The pipeline includes iQ-007 as the lead asset in clinical development and iQ-008 in preclinical development for neuropathic pain and neurodegenerative diseases.

Differentiator

Problem solved

Functional benefit

Products and services

  • iQ-007 First-in-class, orally available EAAT2 positive allosteric modulator designed to restore astrocytic glutamate uptake and break the excitotoxicity cycle. Currently in Phase 1 clinical development for treatment-resistant epilepsy, with mechanism-driven expansion strategies into Parkinson's disease, migraine, and ALS.
  • iQ-008 Preclinical-stage therapeutic program targeting neuropathic pain, epilepsy, and neurodegenerative diseases through EAAT2 modulation.

Quantifiable outcome

  • Strong preclinical efficacy demonstrated across Parkinson's disease, epilepsy, and migraine models
  • +1 more outcomes

Companies that use iQure Pharma

Customer profile

Segments1 record

Ideal customer profiles3 records

iQure Pharma technology and API

Technology

Technology focussed No

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature3 records

iQure Pharma partnerships and signals

Strategic signal

Partnerships

Five partnerships are on record, tiered supporting and core.

  • Atuka Inc.supportingStrategic or Co-development Partner · 18 June 2026Collaboration partner with iQure Pharma on the EAAT2 modulator program for Parkinson's disease, working on preclinical studies across multiple disease-relevant models.
  • University of PadovacoreStrategic or Co-development Partner · 14 October 2025Research collaboration with Associate Professor Laura Civiero from the University of Padova focusing on iQ-007 targeting EAAT2 to further elucidate its underlying mechanism of action. The collaboration aims to better identify and stratify patients who could benefit from this novel astrocyte-targeted therapy while providing deeper insight into molecular pathways governing glutamate uptake.
  • Harvard Medical SchoolcoreStrategic or Co-development PartnerResearch collaboration supporting peer-reviewed research validating EAAT2 mechanism as a novel antiseizure strategy. Published in Annals of Neurology.
  • Boston Children's HospitalsupportingStrategic or Co-development PartnerResearch collaboration supporting peer-reviewed research validating EAAT2 mechanism as a novel antiseizure strategy. Published in Annals of Neurology.
  • Jagiellonian UniversitycoreStrategic or Co-development PartnerCo-author of peer-reviewed research published in Annals of Neurology validating EAAT2 mechanism as novel antiseizure strategy. Home of Prof. Krzysztof Kaminski, iQ-007 inventor.

Scale indicators6 records

Recent moves6 records

Expansion highlights6 records

iQure Pharma competitors and assessment

Company assessment

Direct peers

  • Ovid Therapeutics: Clinical-stage biopharmaceutical company developing medicines for rare neurological and CNS disorders. Comparable as a small-cap CNS biotech pursuing novel mechanisms in neurology.
  • Praxis Precision Medicines: Clinical-stage CNS biotech developing therapies for epilepsy and other central nervous system disorders. Directly comparable as a similarly staged neurology-focused company pursuing novel CNS mechanisms with a small-cap, pipeline-driven profile.
  • Longboard Pharmaceuticals: Clinical-stage CNS company developing treatments for neurological conditions including epilepsy. Comparable as a focused CNS clinical-stage biotech with similar indication overlap and small-cap profile.
  • Xenon Pharmaceuticals: Clinical-stage CNS biopharmaceutical company with a focus on epilepsy and other neurological conditions. Directly comparable as a CNS-focused clinical biotech with active epilepsy pipeline assets.
  • Engrail Therapeutics: Clinical-stage neuroscience company developing therapeutics for CNS disorders including epilepsy and neurodegenerative diseases. Comparable in stage, CNS focus, and small-team biotech execution model.
  • Addex Therapeutics: Clinical-stage biopharmaceutical company specializing in allosteric modulators for CNS disorders. Closely aligned with iQure's allosteric-modulator approach to CNS targets and similar small-cap development profile.

Broad incumbents

  • UCB: Global biopharmaceutical company with a leading CNS/epilepsy franchise (Vimpat, Briviact, Fintepla). Major incumbent in the treatment-resistant epilepsy space iQure is pursuing.
  • SK Biopharmaceuticals: Global biopharmaceutical company focused on CNS therapies including the antiseizure medication Xcopri. Broader incumbent competing in the same epilepsy market iQ-007 is targeting.
  • Jazz Pharmaceuticals: Specialty pharmaceutical company with a significant CNS franchise including epilepsy products (e.g., Epidiolex). Larger incumbent operating across overlapping CNS indications with established commercialization channels.
  • Sage Therapeutics: CNS-focused biopharmaceutical company (now part of Biogen) with approved neurology assets. Broader incumbent operating in overlapping CNS space with much greater capital, scale, and commercialization infrastructure.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat3 records

Key risks6 records

Key highlights6 records

Customer concentration

iQure Pharma social profiles

Digital presence

iQure Pharma financial estimates

Financial estimate

Revenue estimate

Valuation estimate

iQure Pharma leadership team

Management profile

Number of profiles

Profiles3 records

iQure Pharma funding detail

Funding detail

Funding overview

Funding rounds10 records

Investors8 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

iQure Pharma M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about iQure Pharma

What does iQure Pharma do?

iQure Pharma is a clinical-stage biotech company developing first-in-class, orally available small-molecule EAAT2 positive allosteric modulators designed to restore astrocytic glutamate uptake and break the cycle of excitotoxicity in central nervous system disorders. Its lead asset iQ-007 is in Phase 1 clinical development for treatment-resistant epilepsy, with mechanism-driven pipeline expansion into Parkinson's disease, migraine, and ALS, and a second preclinical asset iQ-008 targeting neuropathic pain and neurodegenerative diseases.

Is iQure Pharma a public or private company?

iQure Pharma is a private company. It is classified as venture growth investor backed and is currently operating.

When was iQure Pharma founded?

iQure Pharma was founded in 2019. It employs 1 to 10 people.

Where is iQure Pharma based?

iQure Pharma is headquartered in Princeton, United States, in the North America region.

How does iQure Pharma make money?

One revenue line is on record: drug Development and Licensing.

Who are iQure Pharma's main competitors?

Direct peers on record are Ovid Therapeutics, Praxis Precision Medicines, Longboard Pharmaceuticals, Xenon Pharmaceuticals, Engrail Therapeutics and Addex Therapeutics. Broad incumbents are UCB, SK Biopharmaceuticals, Jazz Pharmaceuticals and Sage Therapeutics.

Does iQure Pharma have an API?

No public API is recorded for iQure Pharma.

What industry is iQure Pharma in?

iQure Pharma's product category is CNS Therapeutics. Its primary akta.pro industry code is HLAAACAH, Neurology/CNS Gene Therapies, with a secondary code of HLACAFAL, Connected Therapeutics & Smart Drug Delivery Monitoring. Its NAICS code is 33451 and its SIC code is 2834.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
BioSpaceiQure Pharma Awarded Grant from The Michael J. Fox Foundation to Advance EAAT2 Program in Parkinson’s DiseaseiQure Pharma received a Michael J. Fox Foundation grant to study EAAT2 modulation with iQ-007 in Parkinson's disease. The grant supports preclinical studies to identify a clinical biomarker for patient selection. The work aims to establish a mechanistic link between glutamate regulation and functional outcomes.PR NewswireiQure Pharma Awarded Grant from The Michael J. Fox Foundation to Advance EAAT2 Program in Parkinson's DiseaseiQure Pharma, a clinical-stage biotech company based in Princeton, New Jersey, has been awarded a research grant from The Michael J. Fox Foundation for Parkinson's Research to advance its EAAT2 modulator program (iQ-007) for Parkinson's disease. The grant will fund preclinical studies across multiple disease-relevant models to demonstrate a correlation between extracellular glutamate regulation and functional outcomes, with the aim of identifying clinical biomarkers to identify patients who may benefit from this treatment. The company, which is also conducting parallel research in epilepsy, ALS, and migraine, is collaborating with the University of Padova and Atuka Inc. on this program.IqurepharmaiQure Pharma Awarded Grant from The Michael J. Fox Foundation to Advance EAAT2 Program in Parkinson’s DiseaseiQure Pharma received a Michael J. Fox Foundation grant to study EAAT2 modulation with iQ-007 in Parkinson's disease. The grant supports preclinical models to link glutamate regulation to functional outcomes and identify a clinical biomarker. The work aims to establish EAAT2 modulation as a therapeutic approach across CNS disorders.SecSEC FORM DiQure Pharma Inc., a Delaware-incorporated company headquartered in Skillman, New Jersey, filed a Form D notice with the SEC for an exempt offering of equity securities under Rule 506(b). The offering has a total amount of $1,750,000, with $1,503,320 already sold to 14 investors as of the first sale on September 9, 2025, leaving $246,680 remaining.PR NewswireiQure Pharma Enters into Research Collaboration with the University of PadovaiQure Pharma, a clinical-stage biotech company focused on CNS disorders, announced a research collaboration with the University of Padova to advance iQ-007, their lead program targeting EAAT2 for glutamate uptake. The collaboration with Associate Professor Laura Civiero's research team aims to better understand the mechanism of action and identify patient populations who could benefit from this astrocyte-targeted therapy. The results will support the clinical development of iQ-007, currently in Phase 1 for treatment-resistant epilepsy, while providing insights into glutamate uptake pathways across neurodegenerative conditions.PR NewswireiQure Pharma Secures US Patent for iQ-007, a First-in-Class Small Molecule Restoring Glutamate Balance in CNS DisordersiQure Pharma announced that the United States Patent and Trademark Office (USPTO) has granted a US patent for iQ-007, the company's first-in-class small molecule that enhances the glutamate transporter EAAT2 to treat CNS disorders. The patent covers both composition of matter and medical use of iQ-007, which is currently in Phase 1 clinical development for treatment-resistant epilepsy with expected completion in December 2025. CEO Pawel Zolnierczyk stated that this milestone strengthens the value of the therapy and positions the US as a key market for new therapeutics.SecSEC FORM DiQure Pharma Inc. filed a Form D notice with the SEC on January 15, 2025, for an exempt offering of equity and debt securities totaling $1,443,786, with the first sale occurring on December 20, 2024. The offering was conducted under Rule 506(b) of Regulation D, with two investors having participated and no minimum investment requirement. The filing was signed by President and CEO Pawel Zolnierczyk, and the company is incorporated in Delaware with its principal place of business in Skillman, New Jersey.SecSEC FORM DiQure Pharma Inc. filed a Form D with the SEC on April 16, 2024, for an exempt securities offering under Rule 506(b) that began sales on April 5, 2024. The company reported raising $220,000 from seven investors in this initial tranche of the offering.Venture Capital Access OnlineiQure Pharma Secures Funding from Ventura BioMed Investors and OKG CapitaliQure Pharma has completed the first closing of its latest funding round, raising $1.2 million to support IND-enabling toxicology studies for its lead therapeutic candidate, iQ-007. The investment was led by Ventura BioMed Investors and OKG Capital, who view this as a step toward completing preclinical development and initiating Phase 1 trials in 2024. This funding aims to accelerate the clinical development of the neuromodulator designed to treat epilepsy and other neurodegenerative conditions.